drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Autologous CD19-directed chimeric antigen receptor T cells (gene-modified cellular immunotherapy) administered as a single IV infusion; engineered T cells recognize CD19 on B-lineage cells to induce cytotoxic depletion and deep B-cell aplasia, reducing autoantibody production and B cell–T cell costimulation in autoimmune diseases.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an anti‑CD19 chimeric antigen receptor bind CD19 on B-lineage cells and trigger T-cell cytotoxicity, leading to profound depletion of CD19+ B cells and plasmablasts, resulting in B‑cell aplasia and reduced autoantibody production and B cell–T cell costimulation.
drug_name
CD19 CAR-T
nct_id_drug_ref
NCT06680388